1. Home
  2. MCD vs NVO Comparison

MCD vs NVO Comparison

Compare MCD & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MCD

McDonald's Corporation

HOLD

Current Price

$268.24

Market Cap

204.6B

ML Signal

HOLD

Logo Novo Nordisk A/S

NVO

Novo Nordisk A/S

HOLD

Current Price

$47.59

Market Cap

197.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCD
NVO
Founded
1940
1923
Country
United States
Denmark
Employees
N/A
69500
Industry
Restaurants
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
204.6B
197.4B
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
MCD
NVO
Price
$268.24
$47.59
Analyst Decision
Buy
Hold
Analyst Count
29
11
Target Price
$344.17
$51.00
AVG Volume (30 Days)
4.2M
11.9M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
2.56%
3.19%
EPS Growth
4.92
N/A
EPS
2.78
N/A
Revenue
$26,885,000,000.00
N/A
Revenue This Year
$7.65
N/A
Revenue Next Year
$6.00
$3.70
P/E Ratio
$95.24
$13.60
Revenue Growth
3.72
N/A
52 Week Low
$264.60
$35.12
52 Week High
$341.75
$71.80

Technical Indicators

Market Signals
Indicator
MCD
NVO
Relative Strength Index (RSI) 37.55 65.49
Support Level N/A $47.52
Resistance Level $311.08 $47.79
Average True Range (ATR) 5.46 1.32
MACD -1.21 0.47
Stochastic Oscillator 15.06 87.73

Price Performance

Historical Comparison
MCD
NVO

About MCD McDonald's Corporation

McDonald's is the world's largest restaurant brand, with nearly $139 billion in systemwide sales across more than 45,000 restaurants and over 100 markets. The quick-service chain built its early reputation on speed, consistency, and affordable hamburgers, and today its global menu spans burgers, chicken, breakfast, and beverages that have helped popularize American fast-food cuisine worldwide. The firm derives the bulk of its revenue from franchise royalties and rent (about 62%), with the remainder stemming from company-operated restaurants across three segments: the United States (39% of systemwide sales), international operated markets (35%), and international developmental/licensed markets (26%).

About NVO Novo Nordisk A/S

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Share on Social Networks: